Hematopoietic progenitor cell mobilization with “just-in-time” PLERIXAFOR (cas 110078-46-1) approach is a cost-effective alternative to routine PLERIXAFOR (cas 110078-46-1) use
-
Add time:08/11/2019 Source:sciencedirect.com
Background aimsHematopoietic cell mobilization with granulocyte-colony stimulating factor (G-CSF) and PLERIXAFOR (cas 110078-46-1) results in superior CD34+ cell yield compared with G-CSF alone in patients with myeloma and lymphoma. However, plerixafor-based approaches may be associated with high costs. Several institutions use a “just-in-time” plerixafor approach, in which plerixafor is only administered to patients likely to fail mobilization with G-CSF alone. Whether such an approach is cost-effective is unknown.
We also recommend Trading Suppliers and Manufacturers of PLERIXAFOR (cas 110078-46-1). Pls Click Website Link as below: cas 110078-46-1 suppliers
Prev:Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and PLERIXAFOR (cas 110078-46-1): Efficacy and Cost Implications
Next:A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus PLERIXAFOR (cas 110078-46-1)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- PLERIXAFOR (cas 110078-46-1) and related macrocyclic amines are potential drug candidates in treatment of malaria by “filling the flap” region of plasmepsin enzymes08/14/2019
- Autologous Stem Cell Mobilization in the Age of PLERIXAFOR (cas 110078-46-1)08/13/2019
- A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus PLERIXAFOR (cas 110078-46-1)08/12/2019
- Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and PLERIXAFOR (cas 110078-46-1): Efficacy and Cost Implications08/10/2019
- Mobilization of Leukemic Cells Using PLERIXAFOR (cas 110078-46-1) as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability08/09/2019
- Etoposide + Granulocyte Colony-Stimulating Factor and Optional PLERIXAFOR (cas 110078-46-1) in Patients Who Failed Chemomobilization with or without PLERIXAFOR (cas 110078-46-1)08/08/2019